CAR T cell

CAR—chimeric antigen receptors—are genetically engineered protein constructs that can be incorporated into a patient’s own cytotoxic T cells with the goal of helping them recognize and fight cancer cells.1,2 This technology creates a new T cell receptor that binds to antigens found on tumor cells and activates the T cell in response to that binding.1

CAR T cell therapy is provided by removing or harvesting T cells from a patient with cancer, transfecting the cells with CAR genes that are directed against the patient’s tumor type, expanding the modified T cell population, and reinfusing the cells back into the patient.1

Download this brochure to learn more about T cell-based immunotherapies for the treatment of cancer.

 

Learn more about CAR T cell targets:
DLL3, FLT3.

Search our clinical trials.

Visit our resources section for further information on modalities currently under investigation.

CAR T: chimeric antigen receptor T cell.

References

1. National Cancer Institute. https://www.cancer.gov/publications/dictionaries/cancer-terms/def/car-t-cell-therapy. Accessed 4/5/2019. 2. American Cancer Society. https://www.cancer.org. Accessed 4/5/2019.